Pre-transplant immune profile defined by principal component analysis predicts acute rejection after kidney transplantation

Front Immunol. 2023 Jul 11:14:1192440. doi: 10.3389/fimmu.2023.1192440. eCollection 2023.

Abstract

Background: Acute rejection persists as a frequent complication after kidney transplantation. Defining an at-risk immune profile would allow better preventive approaches.

Methods: We performed unsupervised hierarchical clustering analysis on pre-transplant immunological phenotype in 1113 renal transplant recipients from the ORLY-EST cohort.

Results: We identified three immune profiles correlated with clinical phenotypes. A memory immune cluster was defined by memory CD4+T cell expansion and decreased naïve CD4+T cell. An activated immune cluster was characterized by an increase in CD8+T cells and a decreased CD4/CD8 ratio. A naïve immune cluster was mainly defined by increased naïve CD4+T cells. Patients from the memory immune profile tend to be older and to have diabetes whereas those from the activated immune profile were younger and more likely to have pre-transplant exposure to CMV. Patients from the activated immune profile were more prone to experience acute rejection than those from other clusters [(HR=1.69, 95%IC[1.05-2.70], p=0.030) and (HR=1.85; 95%IC[1.16-3.00], p=0.011). In the activated immune profile, those without previous exposure to CMV (24%) were at very high risk of acute rejection (27 vs 16%, HR=1.85; 95%IC[1.04-3.33], p=0.039).

Conclusion: Immune profile determination based on principal component analysis defines clinically different sub-groups and discriminate a population at high-risk of acute rejection.

Keywords: acute rejection; biomarker; hierarchical clustering analysis; immune profile; kidney transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • Cytomegalovirus Infections* / etiology
  • Graft Rejection
  • Humans
  • Kidney Transplantation* / adverse effects
  • Principal Component Analysis

Grants and funding

This study was supported by grants from the national “Programme Hospitalier de Recherche Clinique” (PHRC 2005), The Fondation de France (2007), The Fondation transplantation (2008), The “Direction générale de l’Offre de soins – Institut national de la santé et de la recherche médicale” grant (DHOS INSERM 2008) and the interregional “Programme Hospitalier de Recherche Clinique” (PHRC-Interreg 2011).